3结语

    总之，虽有些报道认为NTG不予治疗的自然病程有很大的可变性，有些病情进展明显，而另外有些却可能静止，但对于NTG的病变发展，现仍多数认为是几种机制的共同作用，仍要求尽可能的降低30％以上的眼压，以达到NTG患者的靶眼压水平，减少因眼压造成的视神经损害，保护视功能。同时，因在眼压控制后，部分NTG患者的视神经萎缩仍继续发展，视野进行性缺失，增加眼血流和保护视神经也成为研究的热点。钙通道拮抗剂的应用对改善NTG患者的血循环有益。而前列腺素类制剂在拥有显著降眼压效果的同时，能改善视神经血流，其对NTG患者视功能保护的双重作用正日益得到关注。与此同时，对视神经保护治疗的研究亦日益深入。大量的中药提取物，如灯盏细辛，川芎嗪，复方樟柳碱，刺五加等，被应用于青光眼视神经保护的治疗中。通过降眼压、改善血循环和神经保护等多方面的综合治疗，保护NTG患者的视功能，提高NTG患者的生活质量将有更好的前景。

【参考文献】
  1李凤鸣.中华眼科学.第2版.北京:人民卫生出版社,2005:1747-1844

2 Sim DH, Goh LG, Ho T. Glaucoma pattern a mongst the elderly Chinese in Singapore. An Acad Med Singapore ,1998;27(6):819-823

3 Popovic-Suic S, Sikic J, Vukojevic N, Cerovski B, Nasic M, Pokupec R. Target intraocular pressure in the management of glaucoma.Coll Antropol ,2005;29(Suppl 1):149-151

4 Nakagami T, Yamazaki Y, Hayamizu F, Tanaka C. Effect of ocular hypotensive medications in preventing the progression of visual field damage in patients with normal-tension glaucoma. Nippon Ganka Gakkai Zasshi ,2004;108(7):408-414

5陆云峰.眼灌注压对人视乳头微循环的影响.眼科研究,2004;22(4):209-212

6 Plange N, Remky A, Arend O. Colour Doppler imaging and fluorescein filling defects of the optic disc in normal tension glaucoma. Br J Ophthalmol ,2003;87(6):731-736

7 Leibovitch I, Kurtz S, Kesler A, Feithliher N, Shemesh G, Sela BA. C-reactive protein levels in normal tension glaucoma. J Glaucoma ,2005;14(5):384-386

8 Lip PL, Felmeden DC, Blann AD, Matheou N, Thakur S, Cunliffe IA, Lip GY. Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma. Br J Ophthalmol ,2002;86(11):299-302

9 Yang J, Patil RV, Yu H, Gordon M, Waz MB. T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. Am J Ophthalmol ,2001;131(4):421-426

10 Tezel G, Hernandez R, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol ,2000;118(4):511-518

11贺翔鸽.青光眼首选治疗的策略:药物?手术?国际眼科杂志,2002;2(4):86-88

12 Shigeeda T, Tomidokoro A, Araie M, Koseki N, Yananoto S. Long-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma. Ophthalmology ,2002;109(4):766-770

13 Jongsareejit B, Tomidokoro A, Mimura T, Tomita G, Shirato S, Araie M. Efficacy and complications after trabeculectomy with mitomycin C in normal-tension glaucoma. Jpn J Ophthalmol ,2005;49(3):223-227

14杨磊.正常眼压性青光眼的治疗学研究进展.华南国防医学杂志,2003;17(5):17-20

15 Tomita G, Araie M, Kitazawa Y, Tsukahovra S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye ,2004;18(10):984-989

16 Chen MJ, Ching J, Chou K, Chiou HJ, Hsu WM. Color Doppler imaging of retrobulbar hemodynamics after topical carteolol in normal tension glaucoma. Zhonghua Yi Xue Za Zhi (Taipei) ,2001;64(10):575-580

17 Liu CJ, Ko YC, Cheng CY, Chiu AW, Chou JC, Hsu WM, Liu JH. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology ,2002;109(12):2241-2247

18 Gandolfi SA, Chimino L, Mora P. Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial. Eur J Ophthalmol ,2003;13(7):611-615

19 Otori Y, Tokugawa H, Morimura H, Okada M, Goto H, Miki A, Tano Y. The effect of substituting latanoprost 0.005% for unoprostone 0.12%. Nippon Ganka Gakkai Zasshi ,2004;108(4):207-212

上一页  [1] [2] [3] [4] [5] 下一页